期刊文献+

真核表达MERS-CoV刺突蛋白亚单位的信号肽序列优化研究 被引量:6

Optimization of Signal Peptide Sequences of Spike Protein Subunit of MERS-CoV for Secretory Expression in Eukaryotic Cells
原文传递
导出
摘要 中东呼吸综合征冠状病毒(Middle East respiratory syndrome coronavirus,MERS-CoV)的刺突蛋白(Spike,S)亚单位1(S1)是引起宿主免疫反应和产生中和抗体的主要靶抗原,也是疫苗研发和病原检测的重要靶标,选用适宜的真核表达系统高效表达S1蛋白是进行相关研究的基础。为确定MERS-CoV S1在哺乳动物细胞中高效分泌性表达的信号肽序列,构建了含高斯荧光素酶(Gaussia luciferase,GLuc)、人组织纤溶酶原激活剂(Tissue plasminogen activator,tPA)及小鼠免疫球蛋白G的2a亚型(Mouse immunoglobular G subtype 2a,MIgG2a)7个信号肽(原始序列和改造序列)序列的MERS-CoV S1表达质粒,瞬时转染细胞后,通过Western Blot检测并比较细胞培养上清和裂解液中S1的表达水平及分泌表达效率(条带密度灰度扫描比),并对哺乳动物细胞表达的S1蛋白的纯度与抗原特性进行了分析。结果表明7种信号肽在293T、BHK21和ExpiCHO-S^(TM)三种细胞系统中介导MERS-CoV S1的高效分泌表达的效率各有不同,其中tPA-1信号肽介导S1抗原在ExpiCHO-S^(TM)中具有较高的分泌表达效率与产量,纯化的S1蛋白保持了较好的抗原性。本研究为进一步研发基于MERS-CoV S1的亚单位疫苗及免疫学检测试剂奠定了基础。 MERS-CoV Spike(S) subunit 1(S1) is the main target antigen inducing immune response and neutralizing antibodies in the host, and it was preferred in vaccine development and serological detection. Efficient secretory expression of S1 is benificial for relevant researches. To optimize signal peptide sequences for efficient secretory expression of the MERS-CoV S1 in mammalian cell systems, seven DNA fragments were synthesized to encode native or modified versions of the signal peptide(SP) from Gaussian luciferase(GLuc), human tissue plasminogen activator(tPA) and mouse immunoglobular G subtype 2 a(MIgG2 a). SPs was fused to the5’ end of the MERS-CoV S1 gene respectively to construct recombinant plasmids. And then the recombinant plasmids were transfected into cells, the expression and secretory efficiency of S1 in cell supernatant and lysates were analyzed by Western Blot and band grayscale ratio scanning. Furthermore, the purity and antigenic characteristic of S1 protein expressed in mammalian cells were analyzed by Western Blot and ELISA. The results showed that seven SPs promoted the secretory expression of MERS-CoV S1 in 293 T, BHK21 and ExpiCHOSTM systems with different efficiency. MERS-CoV S1 mediated with tPA-1 SP showed higher level of secretory efficiency and yield in ExpiCHO-STM. The purified MERS-CoV S1 maintained good antigenicity. This study lays the foundation for further development of subunit vaccines and immunological detection researches based on MERS-CoV S1 protein.
作者 宋倩倩 王文玲 詹瑛 鲁福娜 邓瑶 谭文杰 SONG Qianqian;WANG Wenling;ZHAN Ying;LU Funa;DENG Yao;TAN Wenjie(Zhejiang Provincial Key Laboratory of Medical Genelics,School of Laboratory Medicine and Life Sciences,Wenzhou Medical University,Wenzhou 325035,China;National bistitute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,KeyLaboratory of Biosafety,National Health Commission of the People's Republic of Chinu,Beijing 102206,China;Department of Microbiology,School of Basic Medicine,Inner Mongolia Medical University,Hohhot 010110,China)
出处 《病毒学报》 CAS CSCD 北大核心 2019年第1期20-26,共7页 Chinese Journal of Virology
基金 国家重点研发计划(项目号:2016YFD0500301) 题目:重大人兽共患病疫情的快速鉴定 溯源预警及阻断策略研究 国家重点研发计划(项目号:2016YFC1200900) 题目:重要新发突发病原体防治 处置技术与产品研究 国家传染病重大专项"十三五"计划(项目号:2016ZX10004001-003) 题目:基于VLPs和非复制型痘苗病毒载体的MERS-CoV疫苗研发平台的建立~~
关键词 信号肽 中东呼吸综合征冠状病毒(MERS-CoV) 刺突蛋白 分泌表达 Signal peptide Middle East respiratory syndrome coronavirus(MERS-CoV) Spike Secretory expression
  • 相关文献

参考文献1

二级参考文献26

  • 1Lindenbach BD, Thiel HJ and Rice CM. Flaviviridae: the viruses and their replication. In: Knipe DM and Howley PM eds. Fields Virology. Philadelphia, PA: Lippincott Williams & Wilkins, 2007, 1101-1152.
  • 2Houghton M and Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005, 436: 961-966.
  • 3Dubuisson J. Hepatitis C virus proteins. World J Gastroenterol 2007, 13: 2406 -2415.
  • 4Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z and Murthy K, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005, 11: 791-796.
  • 5Lavie M, Goffard A and Dubuisson J. Assembly of a functional HCV glycoprotein heterodimer. Curr Issues MoI Biol 2007, 9: 71-86.
  • 6Stamataki Z, Coates S, Evans M J, Wininger M, Crawford K, Dong C and Fong YL, et al. Hepatitis C vires envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 2007, 25: 7773-7784.
  • 7Ciczora Y, Callens N, Penin F, Pecheur EI and Dubuisson J. Transmembrane domains of hepatitis C virus envelope glycoproteins: residues involved in E1/E2 heterodimefization and involvement of these domains in virus entry. J Virol 2007, 81: 2372-2381.
  • 8Drummer HE, Maerz A and Poumbourios P. Cell surface expression of functional hepatitis C vires E1 and E2 glycoproteins. FEBS Lett 2003, 546: 385-390.
  • 9Falkowska E, Kajumo F, Garcia E, Reinus J and Dragic T. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J Virol 2007, 81: 8072-8079.
  • 10Helle F, Goffard A, Morel V, Duverlie G, McKeating J, Keck ZY and Foung S, et al. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol 2007, 81: 8101-8111.

共引文献5

同被引文献58

引证文献6

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部